跳至主要内容
临床试验/NCT07016568
NCT07016568已完成不适用

Temporary Aortic Occlusion With the Abdominal Tourniquet for Refractory Postpartum Haemorrhage: A Proof-of-Concept Study in a War-Affected Region

LLC UkrMedGroup2 个研究点 分布在 1 个国家目标入组 4 人开始时间: 2024年12月1日最近更新:

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
4
试验地点
2
主要终点
Time to Bleeding Control After AAJT-S Device Application

研究概览

简要总结

The purpose of this study is to evaluate whether a medical device called the Abdominal Aortic and Junctional Tourniquet - Stabilized (AAJT-S) can safely and effectively temporarily stop severe bleeding after childbirth (known as postpartum hemorrhage) when standard treatments fail. The main question the study aims to answer is: Can the AAJT-S device temporarily control life-threatening postpartum bleeding long enough to allow doctors to prepare for surgery and other definitive treatment?

详细描述

This prospective, open-label, non-randomized, proof-of-concept study will assess the feasibility, safety, and preliminary clinical effectiveness of the Abdominal Aortic and Junctional Tourniquet - Stabilized (AAJT-S) device as a temporizing measure for severe postpartum hemorrhage (PPH) due to uterine atony that is unresponsive to standard first-line therapies. The study will be conducted in a tertiary referral center in Zaporizhzhia, Ukraine, located in a conflict-affected region with limited access to timely surgical intervention and blood products.

Eligible participants will be adult postpartum patients (≥18 years) who develop primary PPH with blood loss exceeding 1,000 mL and who fail to respond to pharmacologic uterotonics and balloon tamponade. Patients with hemorrhage due to trauma, coagulopathy, or retained placental tissue will be excluded.

Once standard management protocols are exhausted and eligibility is confirmed, the AAJT-S device will be deployed over the upper abdomen and inflated to 250 mmHg to achieve temporary occlusion of the abdominal aorta and inferior vena cava. The device is intended to reduce pelvic blood flow and thereby control hemorrhage during the critical window required to mobilize a surgical team, arrange blood transfusion, and secure anesthesia.

The device will remain in place for a maximum of 60 minutes, consistent with published safety guidelines. Clinical endpoints will include time to bleeding control, hemodynamic stabilization, need for additional surgical intervention, and total blood loss. Safety endpoints will include thrombotic events, ischemic injury, infections, and any other adverse events related to device use.

Data will be collected prospectively, including demographic characteristics, obstetric history, timing and duration of interventions, and perioperative outcomes. Descriptive statistics will be used to summarize findings, with no formal hypothesis testing due to the pilot nature of the study.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 50 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • Age ≥18 years
  • Clinical diagnosis of postpartum hemorrhage (PPH) refractory to uterotonics and intrauterine balloon tamponade
  • Estimated blood loss greater than 1,000 mL
  • Oral informed consent provided prior to device application

排除标准

  • Patients with postpartum bleeding as a result of trauma, retained placenta or coagulopathy were excluded

结局指标

主要结局

Time to Bleeding Control After AAJT-S Device Application

时间窗: Within 10 minutes of AAJT-S device application

Defined as the time (in minutes) from inflation of the AAJT-S device to visible cessation of external vaginal bleeding in patients with severe postpartum hemorrhage due to uterine atony. Bleeding control will be determined by visual clinical assessment by the attending provider. This measure evaluates the immediate effectiveness of the intervention in stopping hemorrhage and buying time for definitive surgical management or transfusion.

Total Measured Blood Loss (Pre- and Post-intervention)

时间窗: From onset of PPH until bleeding is definitively controlled (typically within 1-6 hours)

Sum of blood loss (in mL), measured by pad/towel weights after AAJT-S use until definitive hemostasis.

Incidence of Device-related Complications

时间窗: From device application through hospital discharge (up to 7 days)

Includes thrombotic events, ischemic injury, skin necrosis, or technical malfunction during/after AAJT-S use.

次要结局

  • Hemodynamic Stabilization Time(First 60 minutes after AAJT-S application)
  • Long-term Maternal Recovery Status(At 6 weeks postpartum)

研究者

发起方
LLC UkrMedGroup
申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验